Home > Oncology > ESMO 2021 > Lung Cancer > Three-year OS follow-up from CASPIAN trial

Three-year OS follow-up from CASPIAN trial

Presented By
Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain
Conference
ESMO 2021
Trial
Phase 3, CASPIAN
The phase 3 CASPIAN trial demonstrated first-line treatment with durvalumab/platinum-etoposide to improve overall survival (OS) versus etoposide alone in patients with extensive stage small-cell lung cancer (ES-SCLC). Three-year median follow-up demonstrated sustained OS benefit. Recently, the phase 3 CASPIAN trial (NCT03043872) demonstrated first-line treatment of ES-SCLC with durvalumab plus etoposide to improve OS versus etoposide alone (HR 0.73; P=0.0047) [1]. This benefit was sustained with more than 2 years follow-up [2]. In addition, a numerical, not statistically significant improvement in OS was observed with durvalumab plus tremelimumab plus etoposide versus etoposide alone [2]. Updated OS results of CASPIAN after a median of more than 3 years follow-up were presented by Dr Luis Paz-Ares (Hospital Universitari...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on